DOI: https://dx.doi.org/10.18565/pharmateca.2021.7.8-14
Г.Р. Бикбавова, М.А. Ливзан, М.М. Федорин
Омский государственный медицинский университет, Омск, Россия
1. Schmidt A., Weber O.F. In memoriam of Rudolf virchow: a historical retrospective including aspects of inflammation, infection and neoplasia. Contrib Microbiol. 2006;13:1–15. Doi: 10.1159/000092961. 2. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30. Doi: 10.3322/caac.21332. 3. Ullman T.A., Itzkowitz S.H. Intestinal inflammation and cancer. Gastroenterology. 2011;140(6):1807–16. Doi: 10.1053/j.gastro.2011.01.057. 4. Chouhan H., Ferrandon S., Devecchio J., et al. A Changing Spectrum of Colorectal Cancer Biology with Age: Implications for the Young Patient. Dis Colon Rectum. 2019;62(1):21–6. Doi: 10.1097/DCR.0000000000001188. 5. Van Der Kraak L., Gros P., Beauchemin N. Colitis-associated colon cancer: Is it in your genes?. World J Gastroenterol. 2015;21(41):11688–99. Doi: 10.3748/wjg.v21.i41.11688. 6. Keller D.S., Windsor A., Cohen R., et al. Colorectal cancer in inflammatory bowel disease: review of the evidence. Tech Coloproctol. 2019;23(1):3–13. Doi: 10.1007/s10151-019-1926-2. 7. Brentnall T.A., Crispin D.A., Rabinovitch P.S., et al. Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis. Gastroenterology. 1994;107(2):369–78. Doi: 10.1016/0016-5085(94)90161-9. 8. Колодей Е.Н. Язвенный колит и рак толстой кишки: актуальные и нерешенные вопросы диагностики. Медицинский альманах. 2013;1(25):74–8. 9. Gao T., Hu Q., Hu X., et al. Novel selective TOPK inhibitor SKLB-C05 inhibits colorectal carcinoma growth and metastasis. Cancer Lett. 2019;31;445:11–23. Doi: 10.1016/j.canlet.2018.12.016. 10. Bezzio C., Festa S., Saibeni S., et al. Chemoprevention of colorectal cancer in ulcerative colitis: digging deep in current evidence. Expert Rev Gastroenterol Hepatol. 2017;11(4):339–47. DOI: 10.1080/17474124.2017.1292129. 11. Dirisina R., Katzman R.B., Goretsky T., et al. p53 and PUMA independently regulate apoptosis of intestinal epithelial cells in patients and mice with colitis. Gastroenterology. 2011;141(3):1036–45. Doi: 10.1053/j.gastro.2011.05.032. 12. Ливзан М.А., Макейкина М.А. Неспецифический язвенный колит: генетика иммунного ответа. Клинические перспективы гастроэнтерологии, гепатологии. 2012;1:28–33. 13. Westbrook A.M., Szakmary A., Schiestl R.H. Mechanisms of intestinal inflammation and development of associated cancers: lessons learned from mouse models. Mutat Res. 2010;705(1):40–59. Doi: 10.1016/j.mrrev.2010.03.001. 14. Goel G.A., Kandiel A., Achkar J.P., et al. Molecular pathways underlying IBD-associated colorectal neoplasia: therapeutic implications. Am J Gastroenterol. 2011;106(4):719–30. Doi: 10.1038/ajg.2011.51. 15. Beaugerie L., Itzkowitz S.H. Cancers complicating inflammatory bowel disease. N Engl J Med. 2015;372(15):1441–52. Doi: 10.1056/NEJMra1403718. 16. Kang M., Martin A. Microbiome and colorectal cancer: Unraveling host-microbiota interactions in colitis-associated colorectal cancer development. Semin Immunol. 2017;32:3–13. Doi: 10.1016/j.smim.2017.04.003. 17. McCoy A.N., Araújo-Pérez F., Azcárate-Peril A., et al. Fusobacterium is associated with colorectal adenomas. PLoS One. 2013;8(1):e53653. Doi: 10.1371/journal.pone.0053653. 18. Khan A.A., Khan Z., Malik A., et al. Colorectal cancer-inflammatory bowel disease nexus and felony of Escherichia coli. Life Sci. 2017;180:60–7. Doi: 10.1016/j.lfs.2017.05.016. 19. Eaden J.A., Abrams K.R., Mayberry J.F. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48(4):526–35. Doi: 10.1136/gut.48.4.526. 20. von Roon A.C., Reese G., Teare J. The risk of cancer in patients with Crohn’s disease. Dis Colon Rectum. 2007;50(6):839–55. Doi: 10.1007/s10350-006-0848-z. 21. Jess T., Rungoe C., Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol. 2012;10(6):639–45. Doi: 10.1016/j.cgh.2012.01.010. 22. Jewel Samadder N., Valentine J.F., Guthery S., et al. Colorectal Cancer in Inflammatory Bowel Diseases: A Population-Based Study in Utah. Dig Dis Sci. 2017;62(8):2126–32. Doi: 10.1007/s10620-016-4435-4. 23. Fornaro R., Caratto M., Caratto E., et al. Colorectal Cancer in Patients With Inflammatory Bowel Disease: The Need for a Real Surveillance Program. Clin Colorectal Cancer. 2016;15(3):204–12. Doi: 10.1016/j.clcc.2016.02.002. 24. Nyboe Andersen N., Pasternak B., Basit S., et al. Association between tumor necrosis factor-α antagonists and risk of cancer in patients with inflammatory bowel disease. JAMA. 2014;311(23):2406–13. Doi: 10.1001/jama.2014.5613. 25. Marley A.R., Nan H. Epidemiology of colorectal cancer. Int J Mol Epidemiol Genet. 2016;7(3):105–14. 26. Askling J., Dickman P.W., Karlén P., et al. Family history as a risk factor for colorectal cancer in inflammatory bowel disease. Gastroenterology. 2001;120(6):1356–62. Doi: 10.1053/gast.2001.24052 27. Ивашкин В.Т., Шелыгин Ю.А., Халиф И.Л. и др. Клинические рекомендации Российской Гастроэнтерологической Ассоциации и Ассоциации Колопроктологов России по диагностике и лечению язвенного колита. Колопроктология. 2017;1(59):6–30. 28. American Society for Gastrointestinal Endoscopy Standards of Practice Committee, Shergill A.K., Lightdale J.R., Bruining D.H., et al. The role of endoscopy in inflammatory bowel disease. Gastrointest Endosc. 2015;81(5):1101–21.e1–13. Doi: 10.1016/j.gie.2014.10.030. 29. Annese V., Daperno M., Rutter M.D. European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis. 2013;7(12):982–1018. Doi: 10.1016/j.crohns.2013.09.016. 30. Rex D.K., Boland C.R., Dominitz J.A., et al. Colorectal Cancer Screening: Recommendations for Physicians and Patients From the U.S. Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2017;153(1):307–23. Doi: 10.1053/j.gastro.2017.05.013. 31. Rubin D.T., Ananthakrishnan A.N., Siegel C.A., et al. ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol. 2019;114(3):384–413. Doi: 10.14309/ajg.0000000000000152. 32. Farraye F.A., Odze R.D., Eaden J., et al. AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology. 2010;138(2):746–74, 774.e1–4; quiz e12-3. Doi: 10.1053/j.gastro.2009.12.035. 33. Cairns S.R., Scholefield J.H., Steele R.J., et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut. 2010;59(5):666–89. Doi: 10.1136/gut.2009.179804. 34. Magro F., Gionchetti P., Eliakim R., et al. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. J Crohns Colitis. 2017;11(6):649–70. Doi: 10.1093/ecco-jcc/jjx008. 35. Куваев Р., Кашин С., Завьялов Д. Роль колоноскопии в диагностике дисплазии и рака толстой кишки при язвенном колите. Врач. 2016;2:70–6. 36. Baker A.M., Cross W., Curtius K., et al. Evolutionary history of human colitis-associated colorectal cancer. Gut. 2019;68(6):985–95. Doi: 10.1136/gutjnl-2018-316191. 37. Berg D.R., Colombel J.F., Ungaro R. The Role of Early Biologic Therapy in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2019;25(12):1896–1905. Doi: 10.1093/ibd/izz059. 38. Abdalla L.F., Chaudhry Ehsanullah R., Karim F., et al. Role of Using Nonsteroidal Anti-Inflammatory Drugs in Chemoprevention of Colon Cancer in Patients With Inflammatory Bowel Disease. Cureus. 2020;12(5):e8240. Doi: 10.7759/cureus.8240. 39. Nadeem M.S., Kumar V., Al-Abbasi F.A., et al. Risk of colorectal cancer in inflammatory bowel diseases. Semin Cancer Biol. 2020;64:51–60. Doi: 10.1016/j.semcancer.2019.05.001. 40. Nagarjun S., Dhadde S.B., Veerapur V.P., et al. Ameliorative effect of chromium-d-phenylalanine complex on indomethacin-induced inflammatory bowel disease in rats. Biomed Pharmacother. 2017;89:1061–66. Doi: 10.1016/j.biopha.2017.02.042. 41. Dobrzycka M., Spychalski P., Łachiński A.J., et al. Statins and Colorectal Cancer – A Systematic Review. Exp Clin Endocrinol Diabetes. 2020;128(4):255–62. Doi: 10.1055/a-0668-5692. 42. Ehrlich A.C., Patel S., Meillier A., et al. Chemoprevention of colorectal cancer in inflammatory bowel disease. Expert Rev Anticancer Ther. 2017;17(3):247–255. Doi: 10.1080/14737140.2017.1283987. 43. Dai C., Jiang M., Sun M.J. Statins and the Risk of Inflammatory Bowel Disease. Am J Gastroenterol. 2016;111(12):1851. Doi: 10.1038/ajg.2016.412. 44. Генкель В.В., Шапошник И.И. Воспалительные заболевания кишечника и статины. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020;30(1):7–13. 45. Cohen-Mekelburg S., Schneider Y., Gold S., et al. Risk of Early Colorectal Cancers Needs to Be Considered in Inflammatory Bowel Disease Care. Digestive Diseases and Sciences. 2019;64(8):2273–79. Doi: 10.1007/s10620-019-05554-1. 46. Ливзан М.А., Макейкина М.А. Воспалительные заболевания кишечника: современные аспекты диагностики и лечения. Consilium Medicum. Гастроэнтерология. 2010;2:60–5. 47. Terdiman J.P., Steinbuch M., Blumentals W.A., et al. 5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease. Inflamm Bowel Dis. 2007;13(4):367–71. Doi: 10.1002/ibd.20074. 48. Velayos F.S., Loftus E.V. Jr, Jess T., et al. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: A case-control study. Gastroenterology. 2006;130(7):1941–49. Doi: 10.1053/j.gastro.2006.03.028.
Автор для связи: Г.Р. Бикбавова, к.м.н., доцент кафедры госпитальной терапии, эндокринологии, Омский государственный медицинский университет, Омск, Россия; galiya1976@mail.ru ORCID:
Адрес: 644099, Россия, Омск, ул. Ленина, 12
Г.Р. Бикбавова, https://orcid.org/0000-0001-9252-9152
М.А. Ливзан, https://orcid.org/0000-0002-6581-7017
М.М. Федорин, http://orcid.org/0000-0002-0238-4664